Follow the Pacira Pharmaceuticals, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1bn. The latest transaction was reported on 1 February 2016 (Acquisition). Among the most active insiders: STACK DAVID M. The full history is accessible without an account.
8
Insider Decl.
n/a
Thresholds
n/a
4 ops.
Buy Volume
n/a
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Pacira Pharmaceuticals, Inc. Buy (bullish), based on 6 analysts. Average price target: US$29.67.
Fundamental score
Ranked 14,892 of 28,803 companies
51.1
score / 100
Value
57
Quality
46
FCF yld13%
Earn yld0.7%
EV/EBITDA11.9x
ROE0.7%
Gross mgn79%
Net mgn1.0%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Pacira Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing non-opioid pain management solutions. It aims to enhance patient care through innovative treatments.